PMID- 35117897
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep
TI  - PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric 
      junction cancer: a retrospective study.
PG  - 5315-5322
LID - 10.21037/tcr-20-1333 [doi]
AB  - BACKGROUND: Nivolumab and pembrolizumab were approved as immune checkpoint 
      inhibitors for third-line treatment of advanced gastric or esophagogastric 
      junction cancer (GC/EGJC) in 2017. However, immunotherapy monotherapy has low 
      efficacy. Apatinib has been proven effective in advanced GC/EGJC. Numerous 
      studies have shown that immunotherapy has a synergistic effect when combined with 
      targeted drug therapy. Based on these facts and to assess the efficacy and safety 
      of programmed death 1 (PD-1) inhibitor and apatinib as combination therapy in 
      patients (pts) with unresectable locally advanced or metastatic GC/EGJC, a 
      retrospective clinical research study was carried out. METHODS: Pts (n=24) 
      received PD-1 inhibitor and apatinib (250 mg once daily) as second- or third-line 
      therapy in this observational, retrospective study. The primary objectives were 
      efficacy and safety. RESULTS: At data cut-off (December 31, 2019), 24 pts were 
      enrolled. Of the 19 pts who were evaluable, the objective response rate (ORR) was 
      26.3% (5/19), the median progression-free survival (PFS) was 3.0 (95% CI: 1.3 to 
      4.7) months, and the median overall survival (OS) was not reached. Grade 3 or 4 
      treatment-related adverse events (TRAEs) occurred in 3 (15.8%) of the 19 pts. 
      These adverse events (AEs) included pruritus, rash, hand-foot syndrome, and 
      increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT). No 
      treatment-related deaths occurred. CONCLUSIONS: Combination therapy of PD-1 
      inhibitor and apatinib showed encouraging clinical activity and demonstrated 
      tolerable toxicity in pts with advanced GC/EGJC. Hence, our work provide 
      rationale for the combination of PD-1 inhibitor and apatinib in advanced GC/EGJC.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Wei, Qing
AU  - Wei Q
AD  - Department of Abdominal Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
AD  - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 
      Hangzhou, China.
FAU - Yuan, Xing
AU  - Yuan X
AD  - Department of Abdominal Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
AD  - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 
      Hangzhou, China.
FAU - Li, Jingjing
AU  - Li J
AD  - Department of Abdominal Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
AD  - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 
      Hangzhou, China.
FAU - Xu, Qi
AU  - Xu Q
AD  - Department of Abdominal Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
AD  - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 
      Hangzhou, China.
FAU - Ying, Jieer
AU  - Ying J
AD  - Department of Abdominal Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
AD  - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 
      Hangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798944
OTO - NOTNLM
OT  - Programmed death 1 (PD-1)
OT  - apatinib
OT  - gastric cancer (GC)
OT  - immune checkpoint inhibitors
OT  - immunotherapy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-1333). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/09/01 00:00
MHDA- 2020/09/01 00:01
PMCR- 2020/09/01
CRDT- 2022/02/04 05:52
PHST- 2020/03/04 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2022/02/04 05:52 [entrez]
PHST- 2020/09/01 00:00 [pubmed]
PHST- 2020/09/01 00:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - tcr-09-09-5315 [pii]
AID - 10.21037/tcr-20-1333 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 Sep;9(9):5315-5322. doi: 10.21037/tcr-20-1333.